drugset
drugset / Trial / NCT05826249

Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects

NCT05826249 ↗

Phase 1 Unknown 20 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label, single-dose, Phase I clinical study and plans to enroll 12-20 healthy elderly subjects aged 65 and above, including 3-6 subjects aged 75 and above, both men and women.

Timeline

Start
2023-04-07
Primary completion
2023-09-30
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 100 mg Oral
Subject simnotrelvir Small molecule 750 mg Oral

Indications

No indication recorded.